title: Current and emerging molecular targets in glioma.
abstract: Gliomas are the most common and lethal neurological cancers. Despite research efforts, the prognosis for patients with malignant gliomas remains poor. Advances in the understanding of cellular and molecular alterations in gliomas have led to the emergence of experimental molecularly targeted therapies. This article summarizes recent progress in the development of targeted therapies for glioma, focusing on emerging molecular targets, including neuropeptide and neurotrophin pathways, glutamate receptors, epigenetic mechanisms and glioma stem cell targets. Recent clinical trials of small molecules and antibodies targeted at growth factor pathways and intracellular signaling cascades are also discussed.
authors.affiliation: Laboratory of Molecular Neuropharmacology, Department of Pharmacology, Institute for Basic Health Sciences, Federal University of Rio Grande do Sul, 90050-170 Porto Alegre, RS, Brazil. rroesler@terra.com.br
authors.forename: Rafael
authors.initials: R
authors.lastname: Roesler
authors.forename: André T
authors.initials: AT
authors.lastname: Brunetto
authors.forename: Ana Lucia
authors.initials: AL
authors.lastname: Abujamra
authors.forename: Caroline Brunetto
authors.initials: CB
authors.lastname: de Farias
authors.forename: Algemir Lunardi
authors.initials: AL
authors.lastname: Brunetto
authors.forename: Gilberto
authors.initials: G
authors.lastname: Schwartsmann
mesh_terms: D001932:Brain Neoplasms / Q000628:therapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005910:Glioma / Q000628:therapy*; D006801:Humans